- Email: [email protected]
Cummins expands Indian joint venture production
Filtration Industry Analyst
NEWS/EXCHANGE RATES
US GRANT FOR ZERO AIR EMISSION POWER PLANT ThermoEnergy Corp, an integrated technologies company that develops and commercialises patented water treatment and clean energy technologies, has announced the start of a US$310,000 federally funded project to develop compact zero air emission power plants for medium to heavy industry. Commonly referred to as Combined Heat & Power (CHP) plants, these systems would allow mainstream industries to switch from natural gas to lower priced alternative fuels to supply their energy needs. This could allow many companies to save hundreds of millions of dollars in energy costs, reduce air pollution, keep their US based plants operating, and lessen dependence on imported energy resources, the company claims. The CHP plants would be based on ThermoEnergy’s advanced patented zero air emission power plant ThermoEnergy Integrated Power System (TIPS). TIPS eliminates the atmospheric emissions of NOx, SOx, mercury, and particulates from power plants that run on coal, oil, natural gas or biomass. It can also capture and recovers carbon dioxide in pressurized liquid form for sequestration or beneficial reuse.
PALL, BIOTRACE TO MARKET AIR MONITORING TECHNOLOGY Pall Corp has entered into an agreement with Biotrace International Plc giving Pall exclusive global marketing and distribution rights to Biotrace’s range of Ascotec environmental air monitoring products for the pharmaceutical industry.
16
February 2006
As part of the worldwide agreement, the two companies will work together on the development of additional innovative products for the rapid detection of contamination. The Ascotec products are used to monitor the quality of the air and compressed gases in the production environment, wherever clean rooms are required for manufacturing of pharmaceuticals, personal healthcare products and cosmetics and in other clinical environments such as hospitals to reliably capture bacteria in the environment for subsequent monitoring. The agreement will provide industry with the ability to access the Ascotec air monitoring technologies to better enable them to achieve the goals of the US FDA Process Analytical Technology (PAT) initiative, the companies report.
Euro 2, Euro 3 and Euro 4 Indian and European standards for diesel emissions. TCL, formed in 1992, has been a successful joint venture between the two companies and manufactures the Cummins B Series engines in India for use in trucks manufactured by Tata Motors (TML), as well as sales by Cummins in India to other applications and OEMs.
EXCHANGE RATES AGAINST THE US DOLLAR Date: 16 February 2005 COUNTRY Australia Austria
0.84
Belgium
0.84
Canada
C$1.16
China
CUMMINS EXPANDS INDIAN JOINT VENTURE PRODUCTION Cummins Inc and Tata Motors have signed an agreement that will allow their joint venture, Tata Cummins Ltd (TCL), to begin manufacturing the ISB engine in the near future. The expansion will significantly increase the number of engines produced by the joint venture and will help strengthen Cummins’ position as a leading producer of engines for the growing medium and heavy-duty commercial vehicle market in India, Cummins says. TCL currently produces approximately 69,000 Cummins B Series engines a year. Under the agreement, TCL will increase its total engine production to 100,000 units within two years and 120,000 units thereafter. The engines produced by TCL will meet
RATE A$1.36
Denmark
8.05CNY DKr6.29
Finland
0.84
France
0.84
Germany
0.84
India
Rs44.26
Italy
0.84
Japan
¥118.02
Malaysia
Rt3.72
Netherlands
0.84
Norway Philippines Singapore
NKr6.81 Peso51.30 S$1.64
South Africa
R6.05
South Korea
Won975.03
Spain
0.84
Sweden
SKr7.90
Switzerland
SFr1.31
Taiwan
T$32.40
Thailand
Bt39.35
UK USA
£0.58 US$1.00
Editorial Office Elsevier Advanced Technology PO Box 150 Kidlington Oxford OX5 1AS United Kingdom Tel: +44 (0)1865 843194 Fax: +44 (0)1865 843971 E-mail:[email protected] Web: www.filtsep.com Editor Liz Nickels Senior Production/Design Controller Lin Lucas Permissions may be sought directly from Elsevier Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; phone: (+44) 1865 843830, fax: (+44) 1865 853333, e-mail: [email protected]. You may also contact Rights & Permissions directly through Elsevier’s home page (http://www.elsevier.com), selecting first ‘Customer Support’, then ‘General Information’, then Permissions Query Form’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: (978) 7508400, fax: (978) 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: (+44) (0)20 7436 5931 ; fax: (+44) (0)20 7631 5500. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher. Address permissions requests to: Elsevier Rights & Permissions Department, at the mail, fax and e-mail addresses noted above. Notice No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
02207 Printed by Mayfield Press (Oxford) Limited, UK.
NEWS/EXCHANGE RATES
US GRANT FOR ZERO AIR EMISSION POWER PLANT ThermoEnergy Corp, an integrated technologies company that develops and commercialises patented water treatment and clean energy technologies, has announced the start of a US$310,000 federally funded project to develop compact zero air emission power plants for medium to heavy industry. Commonly referred to as Combined Heat & Power (CHP) plants, these systems would allow mainstream industries to switch from natural gas to lower priced alternative fuels to supply their energy needs. This could allow many companies to save hundreds of millions of dollars in energy costs, reduce air pollution, keep their US based plants operating, and lessen dependence on imported energy resources, the company claims. The CHP plants would be based on ThermoEnergy’s advanced patented zero air emission power plant ThermoEnergy Integrated Power System (TIPS). TIPS eliminates the atmospheric emissions of NOx, SOx, mercury, and particulates from power plants that run on coal, oil, natural gas or biomass. It can also capture and recovers carbon dioxide in pressurized liquid form for sequestration or beneficial reuse.
PALL, BIOTRACE TO MARKET AIR MONITORING TECHNOLOGY Pall Corp has entered into an agreement with Biotrace International Plc giving Pall exclusive global marketing and distribution rights to Biotrace’s range of Ascotec environmental air monitoring products for the pharmaceutical industry.
16
February 2006
As part of the worldwide agreement, the two companies will work together on the development of additional innovative products for the rapid detection of contamination. The Ascotec products are used to monitor the quality of the air and compressed gases in the production environment, wherever clean rooms are required for manufacturing of pharmaceuticals, personal healthcare products and cosmetics and in other clinical environments such as hospitals to reliably capture bacteria in the environment for subsequent monitoring. The agreement will provide industry with the ability to access the Ascotec air monitoring technologies to better enable them to achieve the goals of the US FDA Process Analytical Technology (PAT) initiative, the companies report.
Euro 2, Euro 3 and Euro 4 Indian and European standards for diesel emissions. TCL, formed in 1992, has been a successful joint venture between the two companies and manufactures the Cummins B Series engines in India for use in trucks manufactured by Tata Motors (TML), as well as sales by Cummins in India to other applications and OEMs.
EXCHANGE RATES AGAINST THE US DOLLAR Date: 16 February 2005 COUNTRY Australia Austria
0.84
Belgium
0.84
Canada
C$1.16
China
CUMMINS EXPANDS INDIAN JOINT VENTURE PRODUCTION Cummins Inc and Tata Motors have signed an agreement that will allow their joint venture, Tata Cummins Ltd (TCL), to begin manufacturing the ISB engine in the near future. The expansion will significantly increase the number of engines produced by the joint venture and will help strengthen Cummins’ position as a leading producer of engines for the growing medium and heavy-duty commercial vehicle market in India, Cummins says. TCL currently produces approximately 69,000 Cummins B Series engines a year. Under the agreement, TCL will increase its total engine production to 100,000 units within two years and 120,000 units thereafter. The engines produced by TCL will meet
RATE A$1.36
Denmark
8.05CNY DKr6.29
Finland
0.84
France
0.84
Germany
0.84
India
Rs44.26
Italy
0.84
Japan
¥118.02
Malaysia
Rt3.72
Netherlands
0.84
Norway Philippines Singapore
NKr6.81 Peso51.30 S$1.64
South Africa
R6.05
South Korea
Won975.03
Spain
0.84
Sweden
SKr7.90
Switzerland
SFr1.31
Taiwan
T$32.40
Thailand
Bt39.35
UK USA
£0.58 US$1.00
Editorial Office Elsevier Advanced Technology PO Box 150 Kidlington Oxford OX5 1AS United Kingdom Tel: +44 (0)1865 843194 Fax: +44 (0)1865 843971 E-mail:[email protected] Web: www.filtsep.com Editor Liz Nickels Senior Production/Design Controller Lin Lucas Permissions may be sought directly from Elsevier Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; phone: (+44) 1865 843830, fax: (+44) 1865 853333, e-mail: [email protected]. You may also contact Rights & Permissions directly through Elsevier’s home page (http://www.elsevier.com), selecting first ‘Customer Support’, then ‘General Information’, then Permissions Query Form’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: (978) 7508400, fax: (978) 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: (+44) (0)20 7436 5931 ; fax: (+44) (0)20 7631 5500. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher. Address permissions requests to: Elsevier Rights & Permissions Department, at the mail, fax and e-mail addresses noted above. Notice No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
02207 Printed by Mayfield Press (Oxford) Limited, UK.